BM-1197: inhibits both Bcl-xL and Bcl-2; has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 60204010 |
| CHEMBL ID | 4085804 |
| SCHEMBL ID | 15892215 |
| MeSH ID | M000608728 |
| Synonym |
|---|
| SCHEMBL15892215 |
| CS-0079466 |
| bm-1197 |
| HY-120882 |
| n-[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-4-methylsulfonyl-1-propan-2-ylpyrrol-3-yl]-5-fluorophenyl]piperazin-1-yl]phenyl]-4-[[(2r)-4-(4-hydroxypiperidin-1-yl)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide |
| dmkvqmfonhhnmz-huesyalosa-n |
| CHEMBL4085804 , |
| bdbm50266959 |
| 1391107-89-3 |
| AKOS040756719 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | Ki | 0.0009 | 0.0000 | 0.1901 | 2.9000 | AID1483485; AID1599454; AID1853840 |
| Bcl-2-like protein 1 | Homo sapiens (human) | Ki | 0.0010 | 0.0000 | 0.4581 | 9.0000 | AID1483486; AID1599455; AID1853841 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1483486 | Inhibition of Bcl-xL (unknown origin) by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| AID1853841 | Binding affinity to Bcl-xL (unknown origin) assessed as inhibition constant by fluorescence polarization assay | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1483487 | Selectivity ratio of compound effect for Bcl-2 (unknown origin) to compound effect for Mcl-1 (unknown origin) | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| AID1483485 | Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| AID1483488 | Selectivity ratio of compound effect for Bcl-xL (unknown origin) to compound effect for Mcl-1 (unknown origin) | 2017 | Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3 | Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules. |
| AID1599455 | Inhibition of Bcl-xL (unknown origin) | 2019 | European journal of medicinal chemistry, Sep-01, Volume: 177 | The chemical biology of apoptosis: Revisited after 17 years. |
| AID1853840 | Binding affinity to Bcl-2 (unknown origin) assessed as inhibition constant by fluorescence polarization assay | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. |
| AID1599454 | Inhibition of Bcl2 (unknown origin) | 2019 | European journal of medicinal chemistry, Sep-01, Volume: 177 | The chemical biology of apoptosis: Revisited after 17 years. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (42.86%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||